Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Other Operating Expenses (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Other Operating Expenses for 4 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses fell 28.85% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Dec 2025, down 21.95% year-over-year, with the annual reading at $5.3 million for FY2025, 21.95% down from the prior year.
  • Other Operating Expenses for Q4 2025 was $1.3 million at bioAffinity Technologies, up from $1.2 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $1.8 million in Q4 2024, with the low at -$16999.0 in Q4 2022.
  • Average Other Operating Expenses over 4 years is $883324.2, with a median of $1.2 million recorded in 2025.
  • Peak annual rise in Other Operating Expenses hit 10351.86% in 2023, while the deepest fall reached 62.45% in 2023.
  • Over 4 years, Other Operating Expenses stood at -$16999.0 in 2022, then soared by 10351.86% to $1.7 million in 2023, then rose by 3.32% to $1.8 million in 2024, then dropped by 28.85% to $1.3 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $1.3 million, $1.2 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.